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Studies of alteration of hepatic cholesterol metabolism in puromycin-
induced nephrotic syndrome in rats. Hypercholesterolemia frequently
accompanies the nephrotic syndrome, but the mechanism responsible
for elevation of plasma cholesterol is poorly understood. Specifically,
the contribution of abnormal hepatic cholesterol metabolism to elevated
concentrations of serum cholesterol has never been studied in depth.
The objective of the present study was to define the alteration of hepatic
cholesterol metabolism in puromycin induced nephrotic syndrome in
rats. Studies involved measurements of specific activities of four
enzymes participating in the maintenance of hepatic cholesterol metab-
olism: HMG-CoA-reductase, the rate limiting enzyme of cholesterol
synthesis; cholesterol 7o-hydroxylase, the rate limiting enzyme in bile
acid synthesis; acyl CoA:cholesterol acyltransferase, the enzyme re-
sponsible for esterification of cholesterol; and cholesterol ester hydro-
lase (CEH), an enzyme which hydrolyzes cholesterol. Multiple injec-
tions of puromycin resulted in a production of nephrotic syndrome with
massive proteinuria, hypoalbuminemia, hypercholesterolemia, ascites
and edema. HMG-CoA-reductase (nmol/hr/mg protein) and cholesterol
7a-hydroxylase activities (nmol/hr/mg protein) in rats with nephrotic
syndrome were not statistically significant as compared to control rats
(4.0 0.7 and 2.0 0.6vs. 3.3 0.4and 1.6 0.2), respectively. Our
results also demonstrate, for the first time, that the normal diurnal
rhythm in HMG-CoA reductase activity is no longer present in the
nephrotic animals. The activities in the nephrotics in the day was 4.0
nmollhr/mg and at night, 3.9 nmol/hr/day, compared to the control
values of 3.3 nmol/hr/mg in the day and 6.9 nmollhr/mg at night. ACAT
activities were 428 78 versus 302 64 pmol/min/mglprotein (P =
NS). CEH activity was markedly increased in the nephrotic syndrome
3.4 0.7 versus 1.1 0.1 nmol/hr/mg protein in control rats. There was
a 25% increase in microsomal free cholesterol in rats with nephrotic
syndrome (P < 0.01). ['4C]-leucine incorporation in TCA precipitable
fraction was not affected by puromycin injection in the first 12 days of
the experiment, suggesting that the determinations of enzyme activities
were not affected by puromycin, a known inhibitor of protein synthesis.
We conclude that the hypercholesterolemia in nephrotic syndrome is
not due to a marked alteration of hepatic cholesterol synthesis or
degradation. A marked threefold increase in CEH was observed, but its
role in the genesis of hypercholesterolemia is uncertain.
Hyperlipidemia is common in renal disease, with hypercho-
lesterolemia being more common than hypertriglyceridemia in
nephrosis, although both occur frequently [1—4]. Virtually every
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class of lipoproteins is affected with alterations of their serum
concentrations, composition, and metabolic rates [5]. As a
result of elevated serum cholesterol, accelerated arteriosclero-
sis and progression of glomerular injury are common complica-
tions of patients with nephrotic syndrome [6—7].
The mechanism responsible for development of nephrotic
hyperlipidemia is complex, multi-factorial, and poorly under-
stood. The prevailing explanation is that in nephrotic syndrome
in response to hypoalbuminemia, there is a compensatory
increase of apoprotein B synthesis, which in turn drives VLDL
production [8—11]. Although stimulation of apoprotein synthesis
caused by hypoalbuminemia may explain enhanced formation
of VLDL, it does not adequately account for hypercholesterol-
emia [12—15].
Hepatic cholesterol homeostasis is maintained by the subtle
poorly understood regulatory mechanism involving LDL recep-
tors, and four key enzymes (Fig. 1): HMG-CoA-reductase
(HMG-CoA-R), the rate limiting enzyme of cholesterol synthe-
sis [16]; cholesterol 7a-hydroxylase (C7aH), the rate limiting
enzyme of bile acid synthesis (or cholesterol degradation) [17];
acyl CoA : cholesterol acyltransferase (ACAT) an enzyme
which esterifies cholesterol [18]; and cholesterol ester hydro-
lase (CEH), an enzyme which hydrolyzes cholesterol esters
[19]. A disordered cholesterol homeostasis in nephrotic syn-
drome could in part explain the occurrence of hypercholester-
olemia.
The objective of the present study was to determine whether
hypercholesterolemia in nephrotic syndrome may be due to
alteration of four enzymes which contribute to the maintenance
of hepatic cholesterol homeostasis.
Methods
Female Sprague-Dawley rats, approximately 250 g body
weight, were purchased from Charles River Laboratories (Bos-
ton, Massachusetts, USA). Rats were housed individually
under controlled lighting conditions (0600 to 1800 hr light phase
in 14 rats and 0300 to 1500 hr dark phase in 8 rats). They were
fed commercial chow (Prolab R.M.H. 3200) and water ad
libitum.
Experimental nephrosis was produced as described previ-
ously [21] by subcutaneous injections of an aminonucleoside
of puromycin (PAN) (6-dimethyl-amino-9-3 '-amino-3 '-deoxy-/3-
D-ribofuranosyl-purine) obtained from Sigma Chemical
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Fig. 1. Schematic diagram of cholesterol/bile
acid synthesis, redrawn and modified, by
permission, from WM Pandak et a! [24].
Abbreviations are: Acetyl-CoA, acetyl-
coenzyme A; HMG-CoA, 3-methylglutaryl
Co-A; HMG-CoA-R, HMG-CoA-reductase;
ACAT. acyl CoA-cholesterol acyl transferase;
CEll, cholesterol ester hydroxylase, c7aOH,
cholesterol 7a hydroxylase.
(St. Louis, Missouri, USA) daily for 12 days. PAN was injected
as a dose of 1.5 mg per 100 g body weight as a saline solution
containing 0.5% PAN. Control animals were also injected
subcutaneously with an equal volume of saline. On day 12,
24-hour urine was collected for protein and creatinine measure-
ment,
All animals survived until sacrifice. Between 8:00 and 9:00
a.m. on the thirteenth day, the rats were anesthetized with
metofane. Bile ducts were cannulated in eight randomly se-
lected rats, and bile was collected for 20 minutes. Blood was
obtained from the vena cava, and animals were sacrificed and
the liver was immediately removed, rinsed in iced saline, and
weighed.
Analytical methods
Standard urine and blood chemistries were performed in the
clinical laboratories of the Medical College of Virginia. Serum
total cholesterol and triglycerides were analyzed on a COBAS
analyzer, Roche Laboratories, using the reagents of the kits
from Boehringer Mannheim and Boehring Diagnostic, Inc.
Bile was extracted according to Foich, Lees and Sloane [221.
Phospholipid phosphorus was determined using the method of
Bartlett [23], and total cholesterol by a modified cholesterol
oxidase method [24, 251. Conjugated bile acids were analyzed
by reverse phase HPLC, using a modification of the methods of
Nakayama and Nakagaki [261.
Preparation of microsomes
Rat liver microsome preparation was carried out at 0°C.
Livers were homogenized in 4 volumes of buffer per g liver
(sucrose 100 mM, KCI 50 mM, EGTA 5 mi, EDTA 30 mM,
dithiothreitol 3 mM and potassium phosphate 100 mM, pH 7.4)
using a Potter-Elvehjem homogenizer. Following centrilugation
at 12,500 x g for 15 minutes the supernatant was decanted to
fresh tubes and centrifuged at 105,000 x g for 90 minutes at 4°C.
The resulting microsomal pellet was suspended in buffer, au-
quoted and frozen once at —20°C for subsequent analysis.
Microsomal protein concentration was determined by the
method of Bradford [27]. Microsomal cholesterol was extracted
and assayed as described previously [281.
Enzyme assays
Activities of 3-hydroxy-3-methylglutaryl-C0A-reductase
(HMG-C0A-R), cholesterol 7a-hydrolase (C7aH), acyl CoA-
cholesterol acyl transferase (ACAT) and cholesterol ester hy-
drolase (CEH) were determined as described by Whitehead et
a! [29], Hylemon et al [30], Erickson et al [31], and Ghosh and
Goldberg [32], respectively. Our assay [30] for CEH discrimi-
nates between neutral and acid pH. It measures neutral CEH
and not lysosomal (acid) CEll.
Protein synthesis
Effect of puromycin on protein synthesis was examined by in
vitro '4C-amino acid incorporation into trichloroacetic acid
(TCA) precipitable fraction, which is often used as an indication
of protein synthesis [33]. Briefly, liver slices were incubated in
Krebs Ringer bicarbonate buffer (pH 7.4) with 0.1 Ci of
uniformly labeled "C leucine and a concentration of 0.065 M.
The incubation took place in a fully oxygenated enclosed vial at
37°C shaking incubator for a period of 90 minutes. At the end of
the incubation, the tissue samples were rinsed in cold PBS and
homogenized in 2 ml of PBS. A 20 d aliquot was kept for
protein determination and cold 50% TCA added to yield a final
concentration of 20% TCA. The precipitate was filtered through
a millipore manifold and washed three times with 5 ml of cold
5% TCA. Then the filter was dried and counted for radioactiv-
ity.
All data are expressed as mean SEM. The group t-test was
used for statistical analysis of data; NS refers to a difference
that is not statistically significant (P > 0.05).
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Fig. 2. Ultrastructural histology of one of the nephrotic rats and the characteristic foot process fusion. Print magnification x 6,400.
Results
Puromycin-injected rats exhibited the signs of severe ne-
phrotic syndrome, namely edema, ascites, hypoalbuminemia,
massive proteinuria, severe hypercholesterolemia, and hyper-
triglyceridemia. The renal histology and the characteristic ul-
trastructural foot process fusion were demonstrated in our
nephrotic rat kidneys (Fig. 2). Table 1 summarizes the urine and
serum chemistry in control and nephrotic rats. The serum
cholesterol and triglyceride concentrations were respectively
650% and 225% more than control animals. Microsomal choles-
terol was significantly increased in nephrotic animals (nephrotic
44.3 2 vs. controls 34.6 2.4 mol/g protein, P = 0.01).
Determination of enzyme activity
Table 2 demonstrates the activity of HMG-CoA-R, C7aH,
ACAT, CEH and microsomal cholesterol measured at 9 a.m.,
which is close to nadir activities for HMG-CoA-R and C7aH.
There was no significant change in HMG-CoA-R activity in
nephrotic versus control rats (4 0.7 vs. 3.3 0.4 nmol/hr/mg).
Also, on a total organ basis, the HMG-CoA-R activity was
similar in nephrotic and control rats. In contrast, HMG-CoA-R
activity measured at midnight, the peak of the diurnal cycle of
reductase activity, was decreased (nephrotic 3.9 0.8 vs.
control 6.9 0.9 nmol/hr/mg, P < 0.058), demonstrating a loss
of diurnal variation in enzyme specific activity.
There was no significant change in the cholesterol 7a-hydrox-
ylase activity between control and nephrotic animals either
when measured close to the nadir of its activity (nephrotic 2
0.6 vs. control 1.6 0.2 nmol/hr/mg) or when measured at its
diurnal cycle peak (nephrotic 2.4 0.4 vs. control 2.4 0.4).
No significant differences were observed with ACAT activities
in rats with nephrotic syndrome versus controls (nephrotic
428 78 vs. controls 302 64 pmollmin/mg protein).
CEH activity was 209% greater in nephrotic rats than in
controls (nephrotic 3.4 0.7 vs. controls 1.1 0.1 nmol/hr/mg
protein, P < 0.01).
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Table 1. Data of control and nephrotic rats
Controls
(N = 7)
Nephrotic(N = 7) P value
Proteinuria mg/day 68.0 7.0 485.00 69.0 <0.001
Serum albumin g/dl 3.3 0.1 2.20 0.3 0.004
Serum cholesterol mg/dl 69.0 4.0 518.00 43.0 <0.001
Serum triglycerides 38.0 3.0 135.00 30.0 0.007
mg/dl
Microsomal cholesterol 34.6 2.4 44.30 2.0 0.01
p.mol/g protein
Serum urea nitrogen 18,0 1.0 126.00 18.0 <0.001
mg/dl
Serum creatinine mg/dl 0.4 0.04 2.80 0.5 <0.001
Creatinine clearance 0.1 0.01 0.02 0.002 <0.001
mi/mm
Body weight at time of 282.0 2.0 242.00 9.0 0.001
sacrifice g
Liver weight at time of 12.1 0.1 15.1 0.4 < 0.05
sacrifice g
Data are mean SEM.
Biliary cholesterol, phospholipids and bile acid secretion
There was no significant change in biliary cholesterol, biliary
phospholipids nor bile acid secretion between nephrotic and
control animals, as shown in Table 2. Bile acid concentration
was increased in nephrotic animals (nephrotic 96 12.5 vs.
control 36 8.7 mol/ml, P < 0.008). The bile flow rates were
significantly reduced in the nephrotic animals (Table 2).
Leucine '4C incorporation in protein synthesis
No significant change was noticed between nephrotic and
control animals in regard to leucine '4C incorporation. The acid
insoluble cpm/mg protein (mean sEM) was 249 80 in the
control group compared to 267 100 in the nephrotic group.
Discussion
The pathogenesis of hypercholesterolemia in nephrotic syn-
drome is uncertain. Two possible mechanisms capable of ex-
plaining the elevation of serum cholesterol include alteration of
hepatic cholesterol homeostasis as a result of increased choles-
terol synthesis, decrease in cholesterol degradation to bile
acids, or a combination of both factors. Alternatively, the
hypercholesterolemia could be due to alteration of lipoprotein
cholesterol kinetics. The present study was designed to deter-
mine whether in nephrotic syndrome there is alteration of
hepatic cholesterol homeostasis. Repeated daily injections of
puromycin until day 12 resulted in clinical features of nephrotic
syndrome such as hypercholesterolemia, hypertriglyceridemia,
proteinuria, hypoalbuminemia, ascites and peripheral edema.
In nephrotic rats, the activities of HMG-CoA-reductase and
cholesterol 7a-hydroxylase, the rate limiting enzymes of cho-
lesterol and bile acid biosynthesis pathways, respectively, were
not altered when compared to control. In relative terms, the
activities of these two enzymes have been previously equated
with the absolute rates of cholesterol and bile acid biosynthesis,
respectively [18, 24]. It should be noted that a statistically
significant increase in microsomal cholesterol was observed in
our study. However, these values for both nephrotic and
control animals fell within the range of previously measured
controls [18, 24]. It is possible that with larger numbers of
Table 2. Hepatic cholesterol controlling enzymes biliary cholesterol,
phospholipid and bile acid secretion
Control(N = 7) Nephrotic(N = 7) P value
HMG-CoA-R activity
nmol/hr/mg protein
day 3.3 0.4 4.0 0.7 NS
night 6.9 0.9 3.9 0.8 < 0.05
Total liver activity, 629.0 105.0 722.0 120.0 NS
nmol/hr
7a-H activity
nmol/hr/mg protein
day 1.6 0.2 2.0 0.6 NS
night 2.4 0.4 2.4 0.4 NS
ACAT activity 302.0 64.0 428.0 78.0 NS
pmol/min/mg protein
GEH activity 1.1 0.1 3.4 0.7 <0.01
nmol/hr/mg protein
Microsomal cholesterol 34.6 2.4 44.3 2.0 <0.01
.unol/g protein
Biliary cholesterol 0.97 0.4 0.93 0.3 NS
p.mol/IOO g body wi/hr
Biliary phospholipids 0.8 0.1 1.3 0.5 NS
pmol/100 g body wt/hr
Bile acid secretion 17.0 3.8 32.0 6.5 NS
i.unol/IOO g body wi/hr
Bile acid concentration 36.5 8.7 96.0 12.5 0.008
,.unol/ml
Bile flow ml/hr 0.5 0.0 0.3 0.1 <0.01
Data are mean SEM.
animals, this statistical difference in microsomal cholesterol
would disappear. In the previous studies, however, we and
others have shown that levels of microsomal cholesterol do not
correlate well with the activities of either HMG-CoA-reductase
or cholesterol 7a-hydroxylase [24, 30]. Cholesterol esterifica-
tion as manifested by ACAT activity was unchanged in the
nephrotic rats while the activity of neutral cytosolic cholesterol
ester hydrolase was increased threefold. The importance of the
increased activity of cholesterol ester hydrolase in overall
cholesterol metabolism is uncertain, as the relationship of this
enzyme to alteration of cholesterol metabolism has not been
systematically studied [18]. Thus, the results of the present
study provide strong evidence that in the nephrotic syndrome,
hepatic cholesterol homeostasis as regulated by four rate-
limiting enzymes is not markedly disturbed. Thus, the genesis
of hypercholesterolemia in nephrotic syndrome does not appear
to originate from a significant perturbation of hepatic choles-
terol metabolism.
Our results also demonstrate, for the first time, that the
normal diurnal rhythm in HMG CoA reductase activity is no
longer present in the nephrotic animals (Table 2). The HMG-
CoA reductase activity in the nephrotic group in the day was
4.0 0.7 nmol/hr/mg, and at night 3.9 0.8 nmol/hr/mg,
compared to the control values of 3.3 0.4 nmol/hr/mg in the
day and 6.9 0.9 nmollhr/mg at night. These findings are
intriguing because we have no explanation why in these ne-
phrotic animals, the rate-limiting point in the cholesterol syn-
thetic pathway loses its diurnal rhythm. It is unlikely due to any
change in the light/dark cycle because the controls were treated
in an identical way. The absorption of nutrients may have been
impaired in the nephrotic group, and their extracellular volume
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is likely contracted because of the hypoproteinemia. Whether
or not such changes affect HMG-CoA reductase activities is
unknown. An increase in HMG-CoA reductase specific activity
is not the reason for the hyperlipidemia associated with nephro-
sis [4]. The diurnal rhythm of HMG-CoA reductase specific
activity is believed to be regulated by fluctuations in glucocor-
ticoid levels throughout the day [18, 24]. It is possible that
diurnal variations in glucocorticoids are altered by nephrosis.
We are not aware of any literature which verifies this point.
The electron microscopy (Fig. 2) of the renal histology shows
fusion of the epithelial foot processes characteristic of minimum
change nephrotic syndrome. However, there is a significant
depression of creatinine clearance and elevated serum creati-
nine concentrations in the nephrotic animals, suggesting that
they were near end-stage renal disease. Thus, the findings of
this study may be more complex, because lipid disorders of
end-stage renal disease may or may not be analogous to the lipid
disorders of minimum change nephrotic syndrome [4, 5, 21].
The nephrotic rats were anorexic partly from the chronic
renal insufficiency. A pronounced degree of negative nitrogen
balance existed due to poor food intake and massive protein-
uria. The proteinuria of the nephrotic rats was 485 mg/day
versus control value of 68 mg/day, leading to protein energy
malnutrition, wasting and marked loss of weight that could not
be compensated for by the edema and ascites. The difference in
weights, although statistically significant, was only 40 g. The
decreased cholesterol synthesis at later stages of nephrosis
seems to be due to the down-regulation of HMG-CoA reductase
through a negative feedback inhibition by the increased choles-
terol content of the liver. It may also be explained in terms of
the nutritional status of the nephrotic animals as they became
partially protein malnourished with progression of chronic renal
insufficiency.
The role of liver in nephrotic syndrome has been studied
previously and controversial results were reported. Cholesterol
synthesis in nephrotic syndrome was described as unchanged
[34], decreased [27, 35] or increased [13, 14, 36]. In most of
these studies, cholesterol synthesis was calculated as incorpo-
ration of(14C) into acetate, a method which has been described
as a relatively inaccurate index of cholesterol synthesis [18]. It
is difficult to reconcile the increased hepatic microsomal cho-
lesterol. However, it is unlikely that cholesterol biosynthesis is
increased when HMG-CoA reductase specific activity is un-
changed, because the latter is a reflection of the rate of
cholesterol biosynthesis.
To the best of our knowledge, there are no studies published
in which the specific activities of all four enzymes participating
in the maintenance of cholesterol homeostasis were determined
simultaneously. In principle, the determination of HMG-CoA
reductase activity is less meaningful if not coupled with the
determination of cholesterol 7a-hydroxylase activity because
the net alteration of hepatic cholesterol metabolism is a result of
the role of cholesterol synthesis and cholesterol degradation. If
the activities of both enzymes are not changed, as was found in
the present study, then one would assume that the relative rates
of cholesterol synthesis and degradation should be similar with
no net flux of cholesterol from the liver to plasma to account for
hypercholesterolemia.
Admittedly, some degree of chronic renal insufficiency may
occur with the nephrotic model. It is not certain that nephrotic
syndrome or uremia affect hepatic cholesterol metabolism
differently. In our studies of 75% nephrectomized rats, there
was no major increase in HMG-CoA-reductase (unpublished
observation). One other point of interest is that the expected
down-regulation in HMG-CoA reductase in the face of elevated
serum cholesterol concentrations did not occur [24, 30]. This
suggests that one of two phenomena is occurring. Either serum
cholesterol uptake by the hepatocyte is decreased or feedback
regulation by cholesterol (and/or oxysterols) is subnormal.
Based on the elevated serum cholesterol concentrations in our
model and the literature's documentation of elevated concen-
trations of LDL [2, 9, 12], our data support an inability to
sufficiently clear the increased lipoproteins.
It is possible that the state of cachexia induced by nephrosis
could affect the activity of HMG-CoA reductase. However,
when compared to sham operated controls, this was not found
to be true. Even if nephrosis leads to an increase in HMG-CoA
reductase activity which is balanced out by a cachectic state, it
is the final specific activity of the enzyme which is pertinent.
In agreement with Goldberg et al [16], who noticed that
increased hepatic sterol mass in nephrotic rats occurred entirely
as free cholesterol and cholesterol ester fraction was lowered,
we found significant increase in microsomal free cholesterol and
the activity of CEH. Both may play a role at least in part in
development of hypercholesterolemia in later stages of ne-
phrotic syndrome.
There are differences between the acute (early) and late
(chronic and more severe) stages in the development and
progression of nephrotic hypercholesterolemia in experimental
nephrosis. In the late and severe stages of nephrotic syndrome,
as our data show, hypercholesterolemia is not due to increased
cholesterol synthesis, decreased formation of bile acids nor
decreased cholesterol secretion into bile. Moreover, down-
regulation mechanisms are operational at late stages of nephro-
sis on the rate limiting enzyme of cholesterol synthesis (HMG-
C0A-reductase). Hypercholesterolemia at these late stages
might be due to compartmental redistribution or mobilization.
We conclude that pronounced dysfunction of hepatic choles-
terogenesis can be excluded as a cause of hypercholesterolemia
observed in nephrotic syndrome. The increased CEH activities
may contribute to the elevated free cholesterol in the mi-
crosomes, with substrate being lipoprotein cholesterol esters.
Furthermore, the hypercholesterolemia of nephrotic syndrome
is most likely due to decreased removal of lipoprotein choles-
terol by the liver rather than the result of increased cholesterol
synthesis.
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